Emerald Mutual Fund Advisers Trust’s KalVista Pharmaceuticals KALV Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.2M	Sell	805,762 -49,699	-6%	-$801K	0.79%	54
2025 Q4	$13.8M	Sell	855,461 -62,514	-7%	-$828K	0.67%	67
2025 Q3	$11.2M	Buy	917,975 +149,003	+19%	+$2.06M	0.58%	69
2025 Q2	$8.69M	Buy	768,972 +160,759	+26%	+$1.97M	0.53%	72
2025 Q1	$7.02M	Buy	608,213 +58,525	+11%	+$597K	0.5%	78
2024 Q4	$4.66M	Sell	549,688 -101,292	-16%	-$1.05M	0.28%	98
2024 Q3	$7.54M	Buy	650,980 +121,615	+23%	+$1.53M	0.39%	84
2024 Q2	$6.24M	Hold	529,365	–	–	0.33%	94
2024 Q1	$6.28M	Buy	+529,365	New	+$7.06M	0.33%	99
2021 Q4	–	Sell	-136,554	Closed	-$2.38M	–	225
2021 Q3	$2.38M	Sell	136,554 -269,658	-66%	-$5.47M	0.08%	158
2021 Q2	$9.73M	Sell	406,212 -10,000	-2%	-$262K	0.32%	107
2021 Q1	$10.7M	Buy	+416,212	New	+$10.9M	0.35%	106

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's KALV Position: Q1 2026 in Review

Emerald Mutual Fund Advisers Trust reduced its KalVista Pharmaceuticals (KALV) stake by 5.8% in Q1 2026, selling an estimated $801K and leaving 805,762 shares worth $16.2M. The position accounts for 0.79% of the portfolio, ranked #54.

Emerald Mutual Fund Advisers Trust first reported a position in KALV in Q1 2021 and has held it in 12 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Emerald Mutual Fund Advisers Trust held 805,762 shares of KalVista Pharmaceuticals worth $16.2M as of Q1 2026.
Emerald Mutual Fund Advisers Trust sold 49,699 KalVista Pharmaceuticals shares in Q1 2026, an estimated $801K.
KalVista Pharmaceuticals made up 0.79% of Emerald Mutual Fund Advisers Trust's portfolio in Q1 2026, its #54 holding.
Emerald Mutual Fund Advisers Trust first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 12 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q1 2026, filed 4 May 2026.